---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-22-037057"
form_type: "8-K"
ticker: "ABCL"
cik: "0001703057"
company_name: "AbCellera Biologics Inc."
filed_at: "2022-11-08T23:59:59+00:00"
generated_at: "2026-06-22T04:01:27.877094+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# AbCellera Q3 revenue $101.4M, net income $0.09/share; program starts up 33%

## Summary
- Total revenue $101.4M (Q3 2021: $5.5M); net income $26.6M ($0.09 basic EPS) vs net loss $21.4M.
- Bebtelovimab royalties contributed $93.3M; research fees $7.5M, milestones $0.4M, licensing $0.2M.
- Cumulative program starts reached 92, up 33% from 69 in Q3 2021; partners increased to 38.
- Cash, cash equivalents and marketable securities stood at $868M.
- R&D expenses $26.6M (up 52% YoY) reflecting continued investment in discovery engine.

## SEC filing metadata
- accession: 0001564590-22-037057
- form_type: 8-K
- ticker: ABCL
- cik: 0001703057
- company_name: AbCellera Biologics Inc.
- filed_at: 2022-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1703057/000156459022037057/0001564590-22-037057-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1703057/000156459022037057/abcl-8k_20221108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-22-037057
- JSON: https://secwatch.observer/filing/0001564590-22-037057.json
- Plain text: https://secwatch.observer/filing/0001564590-22-037057.txt

## Key facts
- Earnings Releases
  AbCellera Biologics Inc. reported Q3 2022 results: revenue $101.4 million, net income $26.6 million, EPS $0.09 per share (basic) and $0.08 per share (diluted).
  - Period: Q3 2022
  - Revenue: $101.4 million
  - Net income: $26.6 million
  - EPS: $0.09 per share (basic) and $0.08 per share (diluted)
  - Result: reported results
  source text: Total revenue of $101 million, compared to $6 million in Q3 2021 • Four program starts in the quarter, bringing cumulative total to 92, up 33% from Q3 2021 • Net earnings of $0.09 per share on a basic and $0.08 on a diluted basis, compared to a net loss of ($0.08) per share (basic and diluted) in Q3 2021
  evidence_url: https://www.sec.gov/Archives/edgar/data/1703057/000156459022037057/0001564590-22-037057-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.